Revvity Inc
NYSE:RVTY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (33.6), the stock would be worth $114.13 (21% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.7 | $94.28 |
0%
|
| 3-Year Average | 33.6 | $114.13 |
+21%
|
| 5-Year Average | 28.7 | $97.58 |
+4%
|
| Industry Average | 29.2 | $99.16 |
+5%
|
| Country Average | 19.6 | $66.68 |
-29%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$12.7B
|
/ |
Dec 2025
$437.9m
|
= |
|
|
$12.7B
|
/ |
Dec 2025
$788.9m
|
= |
|
|
$12.7B
|
/ |
Dec 2026
$847.7m
|
= |
|
|
$12.7B
|
/ |
Dec 2027
$912.3m
|
= |
|
|
$12.7B
|
/ |
Dec 2028
$969m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
R
|
Revvity Inc
NYSE:RVTY
|
10.6B USD | 27.7 | 43.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 24.4 | 25.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 25.7 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.9B CHF | 26.2 | -122.3 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.1B CNY | 16.2 | 15.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 21.7 | 24.9 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 38.9 | 47.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 17.1 | 20.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 24.1 | 29.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Revvity Inc
Glance View
In the fast-evolving landscape of life sciences and diagnostics, Revvity Inc. stands as a vital player, driving innovation and delivering critical solutions to a diverse array of sectors. Established with a focus on precision, Revvity leverages its expertise in diagnostics and scientific services to address pressing global health challenges. The company operates by providing advanced analytical instruments, reagents, and software, enabling researchers and healthcare providers to conduct intricate analyses with unmatched reliability. Their offerings are crucial in areas such as prenatal and neonatal screening, as well as infectious disease detection, where accuracy is of paramount importance. Revenue generation at Revvity hinges on a hybrid model that includes product sales, service contracts, and licensing. By supplying state-of-the-art laboratory equipment, along with complementary services and software, the company creates a comprehensive ecosystem for research and diagnostic testing. The breadth of their portfolio appeals to a varied clientele, from hospital labs to large research institutions, ensuring a steady and diversified income stream. Furthermore, their commitment to research and development fosters long-term partnerships and secures their place at the forefront of scientific advancement, making Revvity a linchpin in both the healthcare and scientific communities.